Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Caspofungin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    39 result(s) found for: Caspofungin. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-004107-20 Sponsor Protocol Number: CAS ELF Start Date*: 2007-10-23
    Sponsor Name:Medical University, Dpt. Internal Medicine, Div. of General Internal Medicine
    Full Title: LUNG PENETRATION OF CASPOFUNGIN INTO EPITHELIAL LINING FLUID
    Medical condition: Plasma and ELF concentrations of Caspofungin will be measured in patients requiring treatment with Cancidas (Caspofungin) for fungal infection (proven or suspected)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003617-34 Sponsor Protocol Number: 41676 Start Date*: 2013-01-30
    Sponsor Name:University Medical Center Groningen
    Full Title: Pharmacokinetics and optimal dosage of caspofungin in critically ill patients with suspected invasive candidiasis.
    Medical condition: suspected invasive candidiasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005032-34 Sponsor Protocol Number: MK-0991-058 Start Date*: 2015-02-27
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Sequential-Panel, Open-Label, Noncomparative Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Caspofungin Acetate in Neonates and Infants Less Than 3 Months of ...
    Medical condition: Empirical therapy for fungal infections
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-004106-87 Sponsor Protocol Number: CAS CVVH Start Date*: 2007-10-23
    Sponsor Name:Meical University, Dpt. Internal Medicine, Div. of General Internal Medicine
    Full Title: CLINICAL PHARMACOKINETICS OF CASPOFUNGIN IN CRITICALLY ILL PATIENTS DURING CONTINUOUS VENO-VENOUS HEMOFILTRATION
    Medical condition: Plasma concentrations of Caspofungin will be measured in patients requiring treatment with Cancidas (Caspofungin) and continuous veno-venous hemofiltration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005030-54 Sponsor Protocol Number: MK-0991-042 Start Date*: 2015-02-24
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Open, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 2 Separate Doses of Caspofungin Acetate in Children Between the Ages of 3 to 2...
    Medical condition: Neutropenic immunosuppressed
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-000424-32 Sponsor Protocol Number: 045 Start Date*: 2004-09-23
    Sponsor Name:Merck Sharp & Dohme BV
    Full Title: A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in the Treatment of Adults with Invasive Candida Infections (Excluding Patients w...
    Medical condition: Non-Blood Invasive Candidiasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004910-27 Sponsor Protocol Number: MK-0991-074 Start Date*: 2015-02-24
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Multicenter, Noncomparative, Open-label Study to Estimate the Safety, Efficacy, and Pharmacokinetics of MK-0991 (Caspofungin) in Japanese Children and Adolescents with Documented Candida or Asp...
    Medical condition: Candida or Aspergillus Infections
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000517-10 Sponsor Protocol Number: CASPO Pk 4-07 Start Date*: 2007-04-23
    Sponsor Name:Hannover Clinical Trial Center GmbH
    Full Title: Monozentrische, prospektiv durchgeführte Studie zur Untersuchung der „steady state“ - Pharmakokinetik von Caspofungin im Plasma, im ELF und in Alveolarmakrophagen bei beatmeten Intensivpatienten mi...
    Medical condition: Immunsupprimierte, beatmete Patienten mit neu aufgetretenem Fieber und radiologisch nachgewiesener Lungeninfiltration, z.B. nach Lungentransplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005210-20 Sponsor Protocol Number: 2005-005210-20 Start Date*: 2006-04-10
    Sponsor Name:CHU Sart-Tilman
    Full Title: Phase II trial of caspofungin as secondary prophylaxis for invasive fungal infections in patients with high-risk hematological malignancies undergoing intensive chemotherapy or hematopoietic stem ...
    Medical condition: Acute leukemia during induction or consolidation therapy. Autologous HSCT for a hematological malignancy. Standard allogeneic HSCT with a myeloablative conditioning regimen.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004911-35 Sponsor Protocol Number: MK-0991-043 Start Date*: 2015-04-03
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Open-Label, Noncomparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in Children with Documented Candida or Aspergillus Infections
    Medical condition: Candida and Aspergillus infections
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-001146-13 Sponsor Protocol Number: A 001 Start Date*: 2006-05-18
    Sponsor Name:University Hospital of Heidelberg
    Full Title: "Investigation of Caspofungin Plasma Concentration and Pharmacokinetic for the Improvement of the Antifungal Therapy in Patients of Surgical Intensive Care Unit"
    Medical condition: hospitalised patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004504-36 Sponsor Protocol Number: 801-00 Start Date*: 2005-12-20
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults.
    Medical condition: Candidiasis (invasive)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10007152 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) IT (Completed) PT (Completed) DE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2006-001549-32 Sponsor Protocol Number: Caspofungin vs Amfotericina Start Date*: 2006-03-01
    Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: Prospectic, multicentric, randomized, controlled trial for the evaluation of efficacy of Caspofungin vs Amfotericina B liposomiale for the empirical treatment of the FUO in children neutropenic for...
    Medical condition: Neutropenia (neutrophil count <500/mm3 for at least 10 days persistent fever for at least 72-96 hours, refrectory to the traetment with wide spectrum antibiotic appropriate for high risk pa...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029354 Neutropenia LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002944-90 Sponsor Protocol Number: EORTC 65041 Start Date*: 2005-07-26
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: A Multicenter, Open, Phase II Study to Estimate the activity and safety of Caspofungin (CASP) in the First-line Treatment of probable and proven Invasive Aspergillosis 'IA) in Patients with Hematol...
    Medical condition: Invasive aspergillosis in patients with haematological malignancies (HM)/autologous Hematopoietic Stem Cell Transplantation (HSCT) – group A- and patients with allogeneic HSCT transplantation – gro...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003488 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-004031-23 Sponsor Protocol Number: E2012AILIVER Start Date*: 2014-08-26
    Sponsor Name:Hopital Erasme
    Full Title: Serum pharmacokinetics of Caspofungin in patients with liver failure.
    Medical condition: The patient admitted for alcoholic hepatitis or decompensated cirrhosis (Child-Pugh score of 10-15) presenting with invasive aspergillosis (proven or probable) and treated by caspofungin.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004871 10024678 Liver failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002079-16 Sponsor Protocol Number: E2013_PK_CASPO70_LIVERFAILURE Start Date*: 2013-09-05
    Sponsor Name:Hospital Erasme
    Full Title: Pharmacokinetics of Caspofungin after one dose in patients with liver failure.
    Medical condition: The pharmacokinetics parameters of caspofungin will be studied for the patient admitted for alcoholic hepatitis or decompensated cirrhosis (Child-Pugh score 7-15).
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004871 10024678 Liver failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004432-70 Sponsor Protocol Number: ema1-profilC-2006 Start Date*: 2006-12-04
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: A multicenter phase II study to evaluate the safety, tolerability and efficacy of caspofungin as prophylactic treatment of invasive fungal infections in patients with acute leukemia undergoing ind...
    Medical condition: neutropenia
    Disease: Version SOC Term Classification Code Term Level
    6.1 10049085 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002084-26 Sponsor Protocol Number: MK0991-064 Start Date*: 2017-01-27
    Sponsor Name:Merck Sharp & Dohme Corp.
    Full Title: A Multicenter, Double-Blind, Randomized, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasiv...
    Medical condition: Invasive Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10064954 Invasive candidiasis LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-003951-18 Sponsor Protocol Number: WSA-CS-008 Start Date*: 2007-05-29
    Sponsor Name:Astellas Global Pharma Development, Inc.
    Full Title: A phase III, double-blind, randomized study to evaluate the safety and efficacy of BAL8557 versus a Caspofungin followed by Voriconazole regimen in the treatment of candidemia and other invasive Ca...
    Medical condition: Treatment of Candidemia and other invasive Candida infections
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10060573 Candidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) HU (Completed) ES (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002630-21 Sponsor Protocol Number: CD101.IV.3.05 Start Date*: 2019-01-10
    Sponsor Name:Cidara Therapeutics Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection versus Intravenous Caspofungin Followed by Optional Oral Fluconazole Step-down in the...
    Medical condition: Candidemia; invasive candidiasis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10064954 Invasive candidiasis LLT
    20.0 100000004862 10060573 Candidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) DE (Completed) GR (Completed) FR (Completed) BE (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 09:26:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA